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Abstract 
THE EFFECT OF 48 HR GLUCOSE ADMINISTRATION 
ON THE HEPATIC P-450 SYSTEM 
by 
John N. Buchholz 
The administration of glucose for 48 hrs to mice 
resulted in a shift of the dose response curve of pento-
barbital, an indication that glucose administration 
significantly sensitized the animals to the effects of the 
drug. Glucose administration produced a reduction in the 
catalytic activity of hepatic microsomal P-450 as measured 
by the in vitro conversion of p-Nitroanisole to p-
Nitrophenol. 
The administration of glucose to rats for 48 hrs 
resulted in prolonged anesthesia after the administration of 
pentobarbital. The spectral binding of hexobarbital and 
methadone to hepatic microsomal P-450 was f otind to be 
significantly reduced following glucose administration. The 
changes in spectral binding were observed in the absence of 
any significant change in the microsomal P-450 content. The 
changes in the spectral binding of hexobarbital and metha-
done to P-450 in glucose treated animals might suggest that 
glucose administration is causing a qualitative or conforma-
tional change in hepatic microsomal P-450 enzymes. Glucose 
administration resulted in an increase in the cytosolic 
protein content which may possibly indicate that glucose is 
inducing enzymes responsible for its metabolism and/or the 
synthesis of lipids from glucose. 
Glucose treatment produced a decrease in hepatic glyco-
gen content and an increase in total microsomal lipid, phos-
pholipid, and fatty acid content. Specific fatty acid and 
phospholipid contents were also measured following glucose 
administration. The results showed that there was an 
increase in microsomal palmitic, palmitoleic, stearic and 
oleic acids as well as the phospholipids phosphatidylcholine 
and phosphatidylethanolamine. Changes in lipid content and 
specific fatty acid content have been shown to be associated 
with changes in microsomal P-450 activity and the binding of 
various substrates to P-450. The data reported in these 
studies suggest that glucose administration was associated 
with quantitative alterations in specific microsomal lipid 
content and that the lipid changes could have influenced the 
activity of microsomal P-450 and the binding of drug sub-
strates to P-450. 
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The endoplasmic reticulum of the eukaryotic cell 
fulfills a number of vital roles in the regulation of 
carbohydrate and lipid metabolism and in the biosynthesis of 
biochemical entities such as cholesterol and steroids. The 
finding that this subfraction of the cell is also involved 
in the metabolism and hence detoxification of xenobiotics 
has made the endoplasmic reticulum a major focus in the 
pharmacological subspecialty known as drug metabolism. The 
bulk of drug metabolism appears to be carried out by enzymes 
located in the endoplasmic reticulum of hepatic cells (1). 
The hepatic endoplasmic reticulum is an intracellular 
membrane which can be subdivided into two distinct subfrac-
tions known as the rough endoplasmic reticulum (RER) and 
smooth endoplasmic reticulum (SER). The RER contains 
ribonucleoprotein particles known as ribosomes which are 
involved in the synthesis of proteins secreted from the cell 
and of proteins destined for incorporation into the endo-
plasmic reticulum and other subcellular membranes. The SER 
although not capable of synthesizing proteins, is involved 
in numerous aspects of lipid metabolism and monooxygenations 
of steroids and xenobiotics. 
Both the SER and RER contain the monooxygenase system 
which is made up of cytochrome P-450, NADPH-cytochrome P-450 
reductase (a FAD- and FMN-containing flavoprotein) and 
1 
phosphatidylcholine as well as other phospholipids and 
neutral lipids. The lipid components are necessary for 
optimal monooxygenase activity (1). 
2 
The cytochrome P-450 system prevents the progressive 
accumulation of lipophilic xenobiotics. Thus detoxification 
appears to be one function of the P-450 system which is 
essential to the survival of humans and other animals alike 
( 1) • 
There are a great multiplicity of substrates which 
undergo hydroxylations involving cytochrome P-450. This 
observation has raised doubts concerning the homogeneity of 
P-450. The theory of heterogeneous P-450's has been able to 
account for the fact that a single substrate such as testos-
terone can undergo several hydroxylations at different car-
bon atoms. Furthermore, the rates of each hydroxylation can 
be altered following pretreatment with different inducing 
agents. The existence of multiple forms of P-450 has been 
established on the basis of spectrophotometric, electro-
phoretic and immunological methods (2). These multiple 
forms of P-450 have different substrate selectivities with 
varying degrees of overlap, are genetically determined and 
they appear to be individually substrate-inducible. Induc-
tion of rat liver microsomal P-450 with phenobarbital and 3-
methylchloanthrene appears to produce two spectrally dif-
ferent enzymes, having absorption maxima at 450 and 448 nm 
respectively (3). Later studies of this phenomenon have 
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shown that a total of seven cytochromes appear to be induced 
by the two inducing agents (4). The heterogeneity of the 
monooxygenase system has the virtue of great versatility 
with respect to its ability to meet the challenge of 
detoxifying many different chemicals utilized in medicine 
and industry today. 
Phospholipids and Fatty Acids 
in the Microsomal System and 
Their Relationship to P-450. 
cytochrome P-450 is an integral protein embedded in the 
membrane matrix of the·endoplasmic reticulum. Consequently, 
the properties of these protein components and the rates of 
specific reactions they catalyze will likely be influenced 
by the nature of the lipid components of the membrane, in 
particular phospholipids. The :membrane matrix provides a 
hydrophobic environment for P-450 enzymes, which mostly 
utilize lipophilic substrates. Thus the membrane consti-
tutes a reservoir for the substrates of P-450 and the 
membrane composition may possibly influence the type of 
substrate-P-450 interactions that occur (1). 
The phospholipid composition of the hepatic endoplasmic 
reticulum membrane is 55% phosphatidylcholine (PC), 20-25% 
phosphatidylethanolamine (PE), 8-10% phosphatidylserine 
(PS), 5-10% phosphatidylinositol (PI), and 4-7% sphingo-
myelin (SM), reveals that the membrane is negatively charged 
at neutral pH. The. ratio of PC to PE is very constant (2 .,.5) 
which suggests that the proper ratio of PC to PE may be very 
4 
important in the normal functioning of membrane bound P-450 
(5,6). Analysis of the fatty acid composition of the rat 
hepatic endoplasmic reticulum showed that the predominant 
fatty acids (approx. 90%) esterified to the number 1 posi-
tion of phosphatidylcholine and phosphatidylethanolamine are 
palmitic (C16:0) and oleic acid (C18:0). At the number 2 
position of phosphatidylcholine and ethanolamine the 
predominant fatty acids (greater than 90%) are arachidonic 
(C20:4) and trilinolein (C18:2). The fluidity of the micro-
somal membrane appears to be determined by the fatty acid 
constituents on the phospholipids and can be altered with 
changes in dietary composition of lipids and fatty acids 
(6,7). Changes in fatty acid composition of the microsomal 
membrane which apparently produce alterations in membrane 
fluidity (6), also results in changes in the catalytic 
activity of microsomal P-450 (7). For example the feeding 
of 3%-10% corn oil diets to rats results in a decrease in 
the duration of hexobarbital induced anesthesia with an 
associated increase in the hepatic microsomal P-450 mediated 
metabolism of hexobarbital and ethylmorphine (7). 
Isolation and reconstitution represents the classical 
biochemical approach to the study of multi-enzyme systems. 
In early studies the P-450 system was initially resolved 
into 3 components, P-450, NADPH cytochrome P-450 reductase 
and a heat stable factor (8). The latter component was 
eventually identified as a lipid, specifically PC (9). 
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Different types of phospholipids have been investigated for 
stimulatory properties of the P-450 system (9). It appeared 
that dilauryl phosphatidylcholine was the most efficient 
lipid in stimulating the activity of the P-450 system in 
reconstitution experiments (10). 
The components of the microsomal P-450 system are 
integrated into the hydrophobic interior of the membrane and 
are in intimate contact with the fatty acyl chains of the 
phospholipids. It remains reasonable to expect that there 
is a pronounced interdependency between the function of P-
450 and the structure of the phospholipid and the physical 
state of the lipid in the microsomal membrane. Extraction 
of the hepatic microsomes with organic solvents will remove 
all neutral lipids and 80% of the phospholipid from the 
membrane, and results in a nearly complete inactivation of 
P-450 dependent hydroxylase activity (11). The activity of 
the monooxygenase system was found to be restored by the 
addition of PC to the lipid free preparations (12). These 
studies seem to suggest that phospholipid has a role in 
determining the activity of the P-450 monooxygenase system 
and that added lipid could renature P-450, partially 
denatured by organic solvent extraction. 
The importance of membrane phospholipid for substrate 
binding and catalysis was recognized over a decade ago. 
Treatment of microsomes with phospholipase A resulted in a 
conversion of P-450 to P-420 (13). Phospholipase C 
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treatment of solublized microsomes will also result in a 
conversion of P-450 to P-420 which reduces the binding of 
various substrates to P-450 and decreases the rate of drug 
metabolism (14,15). Isooctane extraction of liver 
microsomes, which removes PC and PE will significantly 
reduce the binding of drug substrates to P-450 and 
consequently their metabolism (16). There seems to be no 
simple explanation for the phenomena described above. 
However one possible explanation is that the lipid 
components of the membrane maintain the appropriate 
conformational states of P-450 which are necessary for their 
catalytic activity (16). The results do emphasize the 
interdependency between phospholipids and the ability of 
P-450 to bind and oxidize substrates. 
The P-450 enzymes exhibit a characteristic spin state 
alteration when substrates bind to the enzymes. Cytochrome 
P-450 can be either in a low spin state or a high spin 
state. A transition from a low to high spin state and vice 
versa results in conformational changes in the P-450. The 
high spin transition (type 1) is characterized by an absorp-
tion maximum at 380-385 nm and a minimum at 415-420 nm. Low 
spin transition (type 2) is characterized by an absorption 
minimum at 380-385 nm and a maximum at 415-420 nm 
(17,18,19). The binding of cholesterol to specific P-450 
(P-450cam) results in a change from the low spin state to a 
high spin state and the high spin form of the P-450 has a 
- - ~----------------------------------
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higher affinity for cholesterol than the low spin form of 
P-450. Furthermore adrenodoxin (a synthetic steroid) acti-
vates the binding of cholesterol by enhancing the proportion 
of P-450 in the high spin state {20). It appears that some 
ligands such as cholesterol bind preferably to the high spin 
forlil of P-450 where as other ligands such as pregnenolone 
bind preferably to the low spin form of P-450 (20). From 
these observations it appears that the relative affinity of 
P-450 enzymes for similar substrates is dependent on the 
unique conformation of these enzymes associated with their 
spin states (21). In the absence of exogenous substrates 
there is an equilibrium between the high and low spin states 
of microsomal P-450 (22). Investigations considering what 
components of the microsomal membrane are important in 
maintaining spin state equilibria have revealed that phos-
pholipids and fatty acid moieties on the phospholipids have 
significant effects on the spin state equilibria of P-450 
(23,24). 
One of the major roles of the membrane matrix in the 
P-450 mediated catalysis is to provide a hydrophobic envi-
ronment suitable for the hydrophobic compounds which are 
substrates forP-450. A relatively low affinity of the sub-
strate for P--450 can be compensated for by the partitioning 
of a substrate in the membrane, which concentrates hydro-
phobic substrates in the membrane interior (25). More 
recent data suggest that the substrate binding site for 
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P-450 is in intimate contact with the membrane lipid phase 
(26) and that the hydroxylation rate for a substrate such as 
cholesterol is sensitive to the fatty acid composition of 
the lipids (27). 
The hepatic microsomal cytochrome P-450 system has been 
found not only to be involved in the oxidation of xenobiotic 
substances, but also oxidizes endogenous substrates such as 
steroids (28) and fatty acids on phospholipids in the micro-
somal membrane (29). More than a decade ago it was sug-
gested that.fatty acids and some drugs may be oxidized by a 
common hepatic NADPH-dependent mixed function oxidase system 
(30). Fatty acids such as oleic acid and saturated straight 
chain fatty acids also appear to be oxidized by the hepatic 
microsomal P-450 (31). The oxidation of fatty acids in 
microsomal lipids such as arachidonic acid by hepatic P-450 
appears to facilitate the conversion of arachidonic acid to 
prostaglandins (32). Fatty acid oxidation by P-450 has been 
suggested as a mechanism which may facilitate lipid turnover 
in the microsomal membrane and furthermore fatty acids such 
as lauric acid seem to be pref erred substrates for hydroxy-
lation as compared to the hydroxylation of drugs (33). 
Microsomal enzymes are involved in the synthesis of PC, 
PS, PE and the sphingolipids which suggests that the micro-
somal enzymes may play an important role in determining the 
optimal lipid environment for the P-450 enzyme system (34). 
From the preceding discussion it appears that the microsomal 
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P-450 system which metabolizes endogenous and xenobiotic 
substances is a membrane bound system, and that there are a 
number of factors that can apparently affect the activity of 
this system. 
A major concern of contemporary medicine is the adverse 
effects resulting from the clinical use of pharmacologic 
agents. The metabolic clearance of drugs regulates in part 
the duration of action and adverse reactions involved in the 
use of pharmacological agents. Nutritional factors, includ-
ing proteins, carbohydrates, fats, vitamins and minerals 
affect the efficiency of metabolic reactions and hence the 
clearance of various drugs. Since the majority of foreign 
compounds are metabolized by hepatic membrane bound enzymes, 
any factor that alters the binding of substrates to these 
enzymes is likely to cause a change in the rate of metabo-
lism and hence the activity of a drug {35,36). 
There have been a number of factors that have been 
shown to affect the duration of ·action of sedative hypnotics 
such as barbiturates. Starvation of an animal for a short 
period of time results in increased barbiturate induced 
anesthesia (37,39,40). It was suggested that starvation may 
cause a loss of hepatic microsomal protein which apparently 
results in decreased metabolism of the barbiturates and 
hence prolonged effect (39). Rats that are fed a diet high 
in carbohydrates exhibit a prolonged sleep time after the 
administration of pentobarbital and barbital (41). 
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Vitamin B deficient diets when fed to rats resulted in 
longer sleep times after the administration of thiopental 
and pentobarbital. The deficiency of nicotinic acid 
presumably leads to a nicotinamide adenine dinucleotide 
phosphate (NADPH) depletion which is a necessary component 
in the oxidation of these drugs and thus may be responsible 
for the observed effect (42,43). 
Rats that are given an intraperitoneal (i. p.) 
injection of glucose or fructose over a 7 day period will 
exhibit decreased hepatic P-450 content and ethylmorphine N-
demethylase activity (44). These data suggest that glucose 
or sucrose is altering the P-450 content of the hepatic cell 
and thus its ability to metabolize drugs. Mice that are 
allowed to drink a 30% glucose solution for 48 hrs have been 
studied in regards to barbiturate induced anesthesia, dura-
tion of opiate analgesia and the in vitro hepatic microsomal 
metabolism of various barbiturates and opiate analgesics 
(45,46,47). Animals treated with glucose were found to 
sleep significantly longer than controls when administered 
various barbiturates and the analgesic effect of represen-
tative opiates was extended (45,46,47). Furthermore the in 
vitro hepatic microsomal metabolism of representative 
opiates and barbiturates was found to be compromised in the 
glucose treated animals. Kinetic studies on the in vitro 
metabolism of hexobarbital and methadone in glucose treated 
mice showed significant changes in the kinetic parameters Km 
and Vmax (46,47). The changes in the kinetic parameters 
could not be related to quantitative changes in P-450 
content since the P-450 content was not significantly 
altered by 48 hr glucose treatment (46,47). 
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Other studies were designed to test the possibility 
that a metabolite of glucose or glucose itself might act as 
an inhibitor of P-450 activity (48). In these studies the 
cytosolic fraction from treated animals was reconstituted 
with the microsomes from the control animals to see if the 
in vitro metabolism of the substrate p-Nitroanisole (PNA) by 
control microsomes could be inhibited by some component in 
the cytosol from glucose treated animals. The results 
showed that following treatment with glucose the microsomes 
from the glucose treated animals were significantly impaired 
in their ability to·metabolize PNA as compared to control 
microsomes. The results also showed that adding cytosol 
from treated animals to the microsomes from control animals 
did not change the rate of metabolism of PNA by the control 
microsomes. From the data presented above it seems clear 
that the metabolism of barbiturates and opiate analgesics is 
reduced as a result of 48 hr glucose treatment. Following 
the decrease in the metabolism of these compounds, they 
would then presumably accumulate in the blood which would 
account for the increase in the duration of action after 
glucose administration (48). 
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There are fundamental questions that could be asked 
concerning the glucose effect on the microsomal metabolism 
of barbiturates and opiate analgesics. The first question 
is, does glucose or one of its metabolites affect the acti-
vity of the P-450 system indirectly by causing a quantita-
tive change in the amount of P-450 in the microsomes? The 
second question is, can glucose be converted to other sub-
stances such as fatty acids and lipids which can then be 
deposited into the microsomal membrane and produce. a change 
in the activity of the microsomal P-450? The studies com-
pleted here were designed first, to further clarify the in 
vivo effects of glucose administration on pentobarbital 
induced anesthesia by examining the dose response curve of 
pentobarbital in mice; second, to examine the effect of 
glucose treatment on the relative activity of hepatic micro-
somal P•450 in mice utilizing reconstitution studies with 
microsomes and cytosolic components; third, to examine the 
e-ffect of glucose administration on pentobarbital induced 
anesthesia in the rat and the effect of glucose adminis-
tration on the spectral binding of hexobarbital and metha-
done to rat hepatic microsomal P-450; fourth, to observe 
possible changes in the content of hepatic cytosolic 
protein, glycogen, total microsomal phospholipid, total 
microsomal fatty acids, specific microsomal fatty acids and 
phospholipids followinq glucose administration. 
Chapter 2 
METHODS 
The Effect of.Glucose Administration 
on.the.Dose Response Curve of 
Pentobarbital in Mice and the 
in Vitro Metabolism of 
p~Nitroanisole by Mouse 
Liver Fractions 
Male swiss Webster mice (Simonsen Laboratories, Gilroy 
Ca.) weighing 25-28 g were maintained for one week after 
arrival and then randomized into control and glucose treated 
groups for each experiment. The control groups received 
water and food (ad libitum) while the glucose treated groups 
received a 30% glucose solution for 48 hrs and food (ad 
libitum). At 48 hrs the animals were injected i.p. with 
pentobarbital at dose levels of 35, 40, 45, 50, and 55 
mg/kg. Induction of sleep was determined by the loss of the 
righting reflex. Dose response data was analyzed by the 
previously published method of Litchfield and Wilcoxin (38). 
Mice from the control and glucose treated groups were 
randomly selected, sacrificed by cervical dislocation and 
the livers removed. The 9000 xg and microsomal liver frac-
tions were prepared as described by Dixon et al. (40). The 
demethylation of p-Nitroanisole was assayed by the pre-
viously published method of Kato and Gillette (49). 
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The Effect of 48 hr Glucose 
Administration on Pentobarbital 
Sleep Time in Rats 
14 
Male rats (Simonsen Laboratories, Gilroy Ca.) weighing 
200-225 g were randomized into control and glucose treated 
groups. Both groups were treated in the same manner as the 
mice mentioned above. At 48 hrs the animals were injected 
i.p. with a dose of pentobarbital (70 mg/kg). Sleep time 
was determined as the time elapsed between the loss and re-
acquisition of the righting reflex. 
Assay.of Hepatic Glycogen, 
·cytosolic Protein , Microsomal 
Protein, P-450, Microsomal 
Phospholipid, Mic;rosomal Fatty 
Acid, Microsomal Cholesterol. 
and Total Microsomal Lipid 
Following48hr Glucose 
Administration 
Hepatic glycogen content was measured by solubilizing a 
small piece of liver tissue (O.l g) in 30% KOH at 5o0 c for 
one hour and then precipitating the glycogen in 95% ETOH at 
ioo0 c. The glycogen precipitate was resuspended in water 
and then reacted under alkaline conditions with anthrone 
(50). Hepatic cytosolic and microsomal protein was deter-
mined by the Lowry method (51). 
Microsomal P-450 content was measured by the absorbance 
difference in dithionite reduced microsomal suspension and a 
dithionite reduced microsomal suspension mixed with carbon 
monoxide (46). Microsomal lipid was extracted with 1 part 
chloroform and 1 part methanol as described by Bligh and 
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Dyer (51). Lipid was stored at -ao0 c until each analysis 
was performed. An aliquot of the extracted microsomal lipid 
was removed and the phospholipid content was measured by 
determining total phosphorus content as previously described 
by Bartlett (53). Microsomal fatty acid content was deter-
mined by reacting an aliquot of extracted lipid with hydrox-
ylamine and ferric chloride under alkaline conditions as 
described by Stern and Shapiro (54). Microsomal cholesterol 
content was measured colorometrically by reacting an aliquot 
of extracted microsomal lipid with ferric chloride under 
acidic conditions (55). Total microsomal lipid (phospho-
lipid + neutral lipid) was measured by weighing the whole 
microsomal lipid extracts after the chloroform solvent was 
evaporated. 
ouantitation of Specific 
Microsomal Faj:ty Acids 
by Gas Chromatography 
Specific fatty acids were separated and quantitated 
by gas chromatography (GC) on a Suppelco Wax 10 column 
(Suppelco Inc., Belafont Pa.). The fatty acids in a 1 mg 
sample of extracted microsomal lipid were transmethylated in 
boron trifluoride-methanol (14/100 W/V) at 6o0 c for 60 min 
as previously described (53). The fatty acid methyl esters 
(FAME's) of palmitic, palmitoleic, stearic, and oleic acid 
were identified and quantitated using reference FAME's 
obtained from Sigma Chemical company (Sigma, St. Louis Mo.) 
(56). The GC operating conditions were set as follows; 
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helium gas flow 8 ml/min, detector temp 26o0 c, injector temp 
25o0 c, column temp program was 200°c for 15 min then eleva-
ted to.235°c at 2°c;min and held for 10 min before re-
equilibration at 200°c. 
Separation and Ouantitation of 
Microsomal Phosphatidylcholine 
and Phosphatidylethanolamirie 
The quantitation of phosphatidylcholine and ethanol-
amine was carried out by TLC. A 1 mg sample of microsomal 
lipid was spotted on silica gel coated thin layer plates 
(250 microns). The plates were developed in two solvent 
systems as previously described (57). The separated phos-
pholipids were stripped from the plates and total phosphorus 
was determined (53). 
Spectral Binding of Hexobarbital 
and Methadone.to Hepatic 
Microsomal P-450 
The binding of hexobarbital and methadone to microsomal 
P-450 was measured spectrally on a Beckman ACTA MVI dual 
beam spectrophotometer (Beckman Instruments, Irvine Ca.). A 
0.1 ml aliquot of buffer (1.15% KCl in 0.025 M tris, pH 
7.45) was added to disposable 4.0 ml polystyrene reference 
and sample cuvettes (pathlength 1.0 cm) which contained 2~9 
ml of microsomal suspension at a final protein concentration 
of 3.0 mg/ml. The baseline was obtained by scanning the 
/ 
microsomal suspension from 500 to 360 nm in the split beam 
mode. The ··difference spectrum was obtained by! adding o. 1 ml 
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of an appropriate amount of hexobarbital or methadone to 
2.9 ml of microsomal suspension to obtain the concentrations 
given in the results. The cuvette containing the drug was 
placed in the sample chamber and scanned from 500 to 360 nm. 
After the spectral scan was obtained the baseline was sub-
tracted and the difference spectra plotted. The data was 
subjected to a double reciprocal plot to obtain the maximal 
spectral binding (~Amax) and the spectral dissociation 
constant (Ks) as described by Schenkman and Kupfer (58,59). 
Chapter 3 
RESULTS 
Figure 1 describes the effect of 48 hr glucose treat-
ment on the dose response curve of pentobarbital in mice. 
Note that glucose treatment appears to shift the curve to 
the left which resulted in a reduction of the ED 50 by 5.85 
mg/kg (P<O. 05). 
Table 1 describes the effect of 48 hr glucose treatment 
on the in vitro metabolism of p-Nitroanisole by the liver 
9,000 xg supernatant and the microsomal fractions. With 
respect to the 9,000 xg fraction the glucose treated animals 
metabolized one half of the substrate (p-Nitroanisole') as 
did the controls. When the microsomal fraction was used the 
controls lost 37% of their activity but the glucose treated 
only lost approximately 12.5% of their activity (25.17 vs 
18.74 Nmoles p-Nitroanisole metabolized/mg protein/30 min). 
However the difference in microsomal activity between the 
two groups was still highly significant (P<0.01). When the 
control microsomes were re-constituted with control cytosol 
they did not regain their original metabolic activity, but 
retained the microsomal level of metabolism. The microsomes 
from the treated animals reconstituted with cytosol from 
controls showed a slight increase in activity. The recon-
stitution of control microsomes plus cytosol from the 
treated animals and vice versa, did not change the activity. 
These data suggest that glucose treatment does not affect 
18 
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factors in the cytosol other than the possibility of 
inducing enzymes that metabolize glucose and that glucose 
treatment appears.to have a major influence on the metabolic 
activity of the microsomal fraction of the liver cell. 
Table 1 
NMoles p-Nitrophenol Formed/Mg 
Microsomal Protein/JO min 
Group 9,000 xg Microsomes CM+CC CM+TC 
Control 40.4 ± 3.3 25.2 + 1.3 26.4 ± 0.93 26.8 + 0.9 
TM+TC TM+CC 
Glucose 
Treated 21.4 + 0.22 18.7 + 0.7 20.9 + 0.2 21.9 + 0.4 
p < 0.01 p < 0.01 p < 0.01 p < 0.01 
N = 20 N = 20 N = 20 N = 20 
CM+CC = Control Microsomes + Control Cytosol 
TM+TC = Treated Microsomes + Treated Cytosol 
CM+TC = Control Microsomes + Treated cytosol 
TM+CC = Treated Microsomes + Control Cytosol 
Spectral binding studies of hexobarbital and methadone 
to rat microsomal P-450 were carried out in order to examine 
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Figure 1. The effect of 48 hr glucose administration on the 
dose response curve of pentobarbital in mice. Animals in 
each group were injected I.P. with.various doses of 
pentobarbital and the number of animals in each group that 
exhibited anesthesia (loss of righting reflex) was recorded. 
P-450 system. The rat was selected as the species due to 
the fact that many of the spectral binding studies of var-
ious substrates to hepatic P-450 have been carried out in 
the rat (15,17,18,19,20,21,22,24,58,59), which provided an 
extensive data base for the comparison of control and 
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treated animals. Since the binding was to be carried out in 
rats rather than mice, it was necessary to examine the 
effect of glucose treatment on the barbiturate sleep time, 
microsomal protein content and microsomal P-450 content as 
previously examined in mice. The effect of 48 hr glucose 
administration on the duration of pentobarbital induced 
anesthesia is shown in Figure 2. Glucose administration 
results in a highly significant increase (P<0.005) in 
barbiturate induced hypnosis which is consistent with 
previous studies showing an increase in barbiturate anes-
thesia after 48 hr glucose administration in mice. The 
effect of glucose administration on microsomal protein, 
cytosolic protein and microsomal P-450 content is shown in 
Figure 3. Glucose administration causes no significant 
changes in the microsomal protein or P-450 content but does 
induce a significant increase in the cytosolic protein 
content in the treatment group. 
Effect of Glucose on Spectral 
Binding of Hexobarbital and 
Methadone to Microsomal P-450 
The binding of hexobarbital to microsomal P-450 
produced a blue shift (type 1 spectrum) as previously 
UJ 

















Figure 2. The effect of 48 hr glucose administration on the 
duration of pentobarbital induced anesthesia in the rat. 











































































CONTB L GLUCOSE 
TREATED 
Figure 3._ Measurements of rat hepatic microsomal protein, 
P-450 and cytosolic protein content following 48 hour 
glucose administration. Values represent the mean + the 
standard error for 42 animals. 
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published (58). The binding of methadone to microsomal 
P-450 also produced a type 1 spectrum giving an absorption 
maximum at 384 nm and a minimum at 421 nm as shown in Figure 
4. The spectral changes produced by the binding of these 
compounds were concentration dependent and showed satura-
bili ty with increasing amounts of drug added to the micro-
somal suspension. 
Figure 5 shows a plot of the (L\A) absorbance changes 
at 420 nm versus the concentration of hexobarbital in the 
microsomal suspension. This figure shows a decrease in the 
binding of hexobarbital to hepatic microsomal P-450 after 
48 hr glucose administration. Figure 6 is a plot of the .1 A 
values at 421 nm versus the concentration of methadone in 
the microsomal suspension. Glucose administration once 
again is associated with a reduction in the binding of a 
substrate to microsomal P-450. Figure 7 is a double recip-
rocal plot of .1 A at 420 nm versus the concentration of 
hexobarbital. This figure shows that the administration of 
glucose results in a decrease in the apparent spectral dis-
sociation (Ks) and a decrease in the apparent maximal spec-
tral binding (L\Amax) of hexobarbital to hepatic P-450. 
These data are consistent with the previously observed 
decrease in apparent Km and Vmax for the microsomal metabol-
ism of hexobarbital in mice following 48 hr glucose adminis-
tration (46). Figure 8 is a double reciprocal plot illus-
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Figure 4. · The spectral shift induced by methadone following 
the addition of methadone to a rat hepatic microsomal 
suspension. Microsomal protein concentration was 3.0 mg/ml 
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Plot of the absorbance changes (~A) at 420 nm 
concentration of hexobarbital in a hepatic 
suspension from control and glucose treated rats. 
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Figure 6. Plot of the absorbance changes ( J A) at 421 nm 
versus the concentration of methadone in a hepatic micrsomal 
suspension from control and glucose treated rats. Each 




r > .99 __ ------1 
E 60 
c§ I ----G~ucosE 
~ l ----l TREATED 
< I_--'l --










Figure 7. Double reciprocal plot of j A at 420 nm versus 
the concentration of hexobarbital in a hepatic microsmal 
suspension from control and glucose treated rats. Each 
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Figure 8. Double reciprocal plot of J A at 421 nm versus 
the concentration of methadone in a hepatic microsomal 
suspension from control and glucose treated rats. Each 
point is the mean for 6 animals, vertical bars represent the 
standard error. 
30 
binding of methadone to hepatic P-450. Note that glucose 
administration results in an increase in the apparent Ks and 
a decrease in the apparent J Amax. These data are also 
consistent with the previously observed increase in apparent 
Km and a decrease in the apparent Vmax for the hepatic 
microsomal metabolism of methadone in mice following 48 hr 
glucose administration (47). 
The spectral binding of hexobarbital and methadone to 
rat hepatic microsomal P-450 are summarized in Figures 9 and 
10. The two notable features of these figures are (a) the 
effect of glucose treatment on the apparent Ks (decreased Ks 
for hexobarbital and increased Ks for methadone) for both 
hexobarbital and methadone and (b) the decrease in the 
apparent JAmax per unit of P-450 for both hexobarbital and 
methadone in the glucose treated animals. The decrease in 
binding of hexobarbital to P-450 in the treated group is 
approximately 22% as compared to controls. The decrease in 
binding of methadone to P-450 in the treated group is 
approximately 12% as compared to the controls. The data 
from these studies suggest that glucose treatment alters the 
binding of hexobarbital and methadone to hepatic microsomal 
P-450. 
Figure 11 illustrates the effect of glucose adminis-
tration on liver, glycogen content, microsomal phospholipid 
content, total microsomal fatty acids and microsomal choles-























































































Figure 9. Summary of the effect of glucose treatment on the 
spectral binding parameters of hexobarbital to rat hepatic 
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Figure 10. Summary of the effect of glucose treatment on 
the spectral binding parameters of methadone to rat hepatic 


































































































Figure 11. The effect of 48 hr glucose administration on 
rat hepatic glycogen content, microsomal phospholipid, fatty 
acid and cholesterol content. Values represent the mean ± 
the standard error. 
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glycogen content (16% reduction in treated animals as 
compared with controls). Phospholipid content and total 
fatty acid content in the microsomes increase significantly 
(P<0.02 and P<0.005 respectively) following glucose treat-
ment. The increase in phospholipid content in the treated 
animals is approximately 26% as compared to controls and the 
increase in fatty acid content in the treated animals is 
approximately 22% as compared to controls. It is interes-
ting to note that a 22% increase in microsomal fatty acid 
content is associated with a 22% decrease in the maximal 
spectral binding of hexobarbital to P-450 and a 12% reduc-
tion in the binding of methadone to P-450. 
Glucose administration appears to have an effect on 
total microsomal lipid content and on the content of various 
fatty acid in the microsomal membrane (Figure 12). Glucose 
administration results in highly significant increases in 
palmitic, palmitoleic and oleic acid (P<0.005). There is 
also an increase in stearic acid, but the level of signif i-
cance (P<0.05) is not as great as the other three fatty 
acids. These data may suggest that glucose is being 
converted to specific fatty acids and consequently lipid 
which can then be deposited in the microsomal membrane. 
Quantitation of the two predominant lipids in the 
microsomal membrane, phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE), following glucose adminis-





















































Figure 12. The effect of 48 hr glucose administration on 
rat hepatic microsomal lipid, palmitic acid, palmitoleic 
acid, stearic acid and oleic acid contents. Values 

























CON R GLUCOSE 
TREATED 









Figure 13. The effect of 48 hr glucose administration on rat 
hepatic microsomal phosphatidyl choline and phosphatidyl 
ethanolamine contents. Values represent the mean ± the 
standard error. 
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administration results in a significant increase in both PC 
and PE (P<0.02 and P<0.05 respectively). The increase in PC 
content was 33% and the increase in PE content was approxi-
mately 22% over the control values. 
Chapter 4 
DISCUSSION 
Previous studies have shown that 48 hr glucose 
administration result in a significant increase in the 
duration of pentobarbital induced anesthesia and opiate 
induced analgesia (45,46,47). The data reported in these 
studies confirmed the glucose effect showing that glucose 
administration decreases the amount of pentobarbital neces-
sary to achieve anesthesia (Figure 1). A possible theory 
explaining the effect of glucose administration on the dura-
tion of action of barbiturates and opiate analgesics is that 
glucose administration may somehow reduce the hepatic micro-
somal metabolism of these two groups of drugs. The reduced 
metabolism might then lead to higher blood levels of the 
drugs and hence prolonged effect. One study showed that 
mice treated for 48 hrs with glucose had higher blood levels 
of pentobarbital (46) and that the hepatic in vitro micro-
somal metabolism of compounds such as p-Nitroanisole, pento-
barbital, hexobarbital and methadone were significantly 
reduced (45,46,47). The data presented in Table 1 confirm 
that glucose administration does indeed impair the in vitro 
hepatic microsomal metabolism of p-Nitroanisole in mice. 
The data also appear to indicate that a metabolite of 
glucose or glucose itself is not directly responsible for 
the reduction in metabolism as exemplified by the reconsti-
tution of the cytosolic and microsomal fractions. What 
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appears to be clear from these data (Table 1) is that the 
microsomal system itself is altered in some way after 
glucose administration which results in reduced enzymatic 
activity. This information is consistent with previous 
observations showing that glucose administration appears to 
exert its effect on the hepatic microsomal system resulting 
in a significant reduction in P-450 enzyme activity (45,46). 
Other animal species such as the rat have been shown to 
be affected by the administration of glucose or sucrose. In 
one previously published study the administration of glucose 
or sucrose in the diet resulted in prolonged sleep time 
after the administration of pentobarbital (35). The data 
presented in Figure 2 are consistent with this previous 
observation, showing that 48 hr glucose administration to 
rats results in highly significant increases in pento-
barbital induced anesthesia. These data are also consistent 
with the previously observed prolonged pentobarbital anes-
thesia in mice after 48 hr glucose administration (45,46). 
The i.p. administration of glucose or sucrose to rats for 7 
days will apparently result in a decreased hepatic micro-
somal P-450 content with a concomitant reduction of the in 
vitro microsomal P-450 mediated metapolism of ethylmorphine. 
The in vivo assessment of hepatic drug metabolic activity 
using the antipyrine test confirmed the parallel decrease in 
microsomal activity in vitro (44). The data reported in our 
studies (Figure 3) did not show any significant quantitative 
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change in microsomal protein or P-450 content following 48 
hr glucose administration. The previously published studies 
by Hartshorn, et al. (44) reportedly saw no changes in rat 
hepatic microsomal protein or P-450 content within 2 days of 
initial treatment with glucose or sucrose which is consis-
tent with the data reported in our laboratory (Figure 3). 
However significant changes in P-450 content did arise 
within 5 days after initial treatment (44). Peters and 
Strother showed that the 48 hr administration of glucose to 
mice apparently does not result in a significant quantita-
tive change in hepatic microsomal protein or P-450.content 
(46) which is consistent with the data obtained in the rat 
as noted in Figure 3. These results may suggest that the 
effect of 48 hr glucose administration on pentobarbital 
anesthesia in mice (45,46) and rats is related to reduced 
hepatic metabolic activity. However the data reported here 
(Figure 3) and in other published studies (46) do not sup-
port the theory that the effect of glucose administrat.ion on 
drug action is related to quantitative changes in hepatic 
microsomal P-450 content. 
Although hepatic microsomal protein content and P-450 
content did not significantly change following glucose 
treatment, the cytosolic protein content did significantly 
increase in the glucose treated animals (Figure 3). The 
increased cytosolic protein content might suggest that the 
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increased glucose intake may be inducing enzymes that meta-
bolize glucose or synthesize lipids. 
In the absence of significant quantitative changes in 
hepatic microsomal P-450 content following 48 hr glucose 
treatment, binding studies were carried out to examine the 
effect of glucose treatment on the interaction between P-450 
and the substrates hexobarbital and methadone. The binding 
of hexobarbital to microsomal P-450 produced a type 1 spec-
trum with an absorption maximum at 385 nm and minimum at 420 
nm which is consistent with previous reports by Schenkman on 
the spectral binding of hexobarbital to rat hepatic micro-
somal P-450 (58). The binding interaction of methadone to 
rat hepatic P-450 also produced a type l spectral shift and 
is shown in Figure 4 since its spectrum has not been pre~ 
viously published. The absorption maximum was 384 nm and 
minimum at 421 nm. The.type l spectral shifts produced by 
the binding of hexobarbital and methadone indicate a shift 
in the spin state of the heme moiety of cytochrome P-450 to 
the high spin state (58,60). Substrates that induce type 1 
spectral shifts in microsomal P-450 have been shown to 
exhibit a preferential binding to the high spin form of 
P-450 (20,61). 
The administration of glucose to rats for 48 hrs 
results in a significant reduction in the spectral binding 
of hexobarbital and methadone to P-450 (Figures 4,5). The 
reduced interaction between microsomal P-450 and these two 
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substrates (as indicated by the reduction in spectral 
binding) may off er a possible explanation for the previously 
observed reduction of the in vitro hepatic microsomal metab-
olism of hexobarbital in glucose treated mice (46,47). 
Plotting the spectral binding data (Figures 7,8) by the 
double reciprocal method showed a change in both the spec-
tral dissociation constant (Ks) and the maximal spectral 
binding ( .d Amax) for hexobarbi tal and methadone. Changes in 
the spectral binding parameters have been suggested in some 
cases to be indicators of qualitative or conformational 
changes in P-450 (7,20,58,60,61). The data presented here 
(Figures 7,8) suggest that glucose administration may be 
effecting a qualitative change in the microsomal P-450 which 
would then be responsible for the decrease in the Li.Amax and 
the changes in the Ks. The increase in Ks for methadone 
indicates that the affinity of the microsomal P-450 has 
decreased following glucose administration. The data in 
Figure 3 show that P-450 content is not significantly 
changed by glucose administration, which provides evidence 
that the observed changes in the binding of hexobarbital and 
methadone (Figures 7,8) may be due to qualitative or confor-
mational changes in the P-450 enzymes. 
The decrease in Ks and Amax-for the spectral binding 
of hexobarbital to P-450 is consistent with the data 
reported by Peters and Strother (46) showing a decrease in 
' 
Km and Vmax for the microsomal metabolism of hexobarbit~l 
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following glucose administration in mice. The increase in 
Ks and decrease in ~Amax (Figure 8) for the spectral 
binding of methadone to P-450 is consistent with the data 
published by Strother and Chau (47) showing an increase in 
Km and decreased Vmax for the microsomal metabolism of 
methadone following glucose administration in mice. In 
these published results (46,47) it was also noted that there 
was no significant change in microsomal P-450 content which 
suggested that the altered kinetics for the metabolism of 
hexobarbital and methadone was possibly due to some physical 
change in the microsomal P-450 system as opposed to a 
quantitative change in P-450 enzyme content. 
The summary of the spectral binding of hexobarbital and 
methadone (Figures 9,10) showed that glucose administration 
to rats for 48 hrs significantly changes Ks and ~Amax for 
hexobarbital and methadone. The most notable feature in 
these figures is that glucose administration results in a 
decrease in Amax per unit of P-450 for both hexobarbital 
(Figure 9) and methadone (Figure 10). The binding data for 
hexobarbital and methadone (Figures 7,8,9,10,) combined with 
the quantitative data on P-450 (Figure 3) show that glucose 
administration alters the ability of the P-450 system to 
bind substrates as compared to the controls. 
The precise mechanism by which glucose administration 
alters the binding of hexobarbital and methadone to hepatic 
microsomal P-450 is not very clear. Two mechanisms have 
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been suggested. The first possibility is that glucose may 
be producing its effect on P-450 in some indirect manner 
possibly by altering the physical state of the microsomal 
P-450 system possibly through changes in lipid quantity and 
type. In order to consider an "indirect mechanism" for the 
glucose effect the fate of glucose in the liver needs to be 
considered. Previous studies by Touvinen and Bender (62) 
showed that the feeding of glucose or sucrose results in an 
increased lipid content in the rat liver. MacDonald and 
Roberts (63) showed that high glucose and fructose diets 
will result in the increased in vivo incorporation of 14c-
glucose into liver lipids. Hartshorn et al. (44) have also 
shown that the administration of glucose in the diet will 
. \ 
result in the increased capacity of the liver to convert 
glucose to fatty acids and lipid, while Fitch and Chaikoff 
(64) showed that carbohydrate administration produced sig-
nificant changes in enzymes responsible for the production 
of lipids. 
The data reported in these studies examine some of the 
possible end products of glucose metabolism and the rela-
tionship between the end products of glucose metabolism and 
the microsomal P-450 system. The administration of glucose 
for 48 hrs resulted in a significant reduction in the 
hepatic glycogen content (16% reduction in glucose treated 
animals, Figure 11). Fouts et al. (65) have shown that 
reduced liver glycogen content after the administration of 
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epinephrine would result in a significant increase in 
hexobarbital induced sleep and a reduction in microsomal 
metabolic activity. However in the study reported by Fouts 
et al. (65) the hepatic glycogen content was reduced to 42% 
of the control value before any significant change in sleep 
time or microsomal metabolic activity occurred. Dixon et 
al. (66) showed that hepatic microsomal enzyme activity and 
glycogen content are not always correlated. Although the 
reduction in glycogen content reported here was significant, 
it is difficult in light of other studies (65,66) to make 
any inference as to the contribution of the observed change 
in glycogen content and the increase in pentobarbital sleep 
time. 
Glucose administration for 48 hrs did not result in a 
significant change in hepatic microsomal cholesterol content 
(Figure 11) which is consistent with other published studies 
showing that sucrose enriched diets (62) and glucose 
enriched diets (67) do not alter hepatic cholesterol 
content. 
Hepatic microsomal phospholipid content and fatty acid 
content apparently increase following 48 hr glucose treat-
ment (Figure 11). These data may possibly indicate that 
glucose is being converted to lipids which are then depos-
ited in the microsomal membrane. The increased microsomal 
lipid content is consistent with the increase in cytosolic 
protein content (Figure 3) which might suggest that glucose 
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administration is inducing enzymes that metabolize glucose 
and/or synthesize lipid. Other studies have shown increases 
in total hepatic lipid content (62,67) following glucose or 
sucrose administration. The data gathered here (Figure 11) 
show that lipid content is specifically increased within the 
endoplasmic reticulum. Studies in the past have shown that 
lipid is a necessary component in maintaining the appro-
priate physical state and hence activity of P-450 (9,12). 
Therefore it is possible that altered lipid content in the 
microsomal membrane may cause a physical change in P-450 as 
indicated by the altered binding of hexobarbital and metha-
done to microsomal P-450 following glucose administration 
(Figures 7,8,9,10). 
Wade and Norred (68) showed that the feeding of 3%-10% 
corn oil to rats resulted in an increase in microsomal lipid 
and a corresponding increase of the in vitro microsomal 
metabolism of ethylmorphine and hexobarbital. Hexobarbital 
induced anesthesia was also found to be reduced in the 
animals fed the high fat diet. Gower and Willis (69) 
conducted a study in which rats were fed a fat diet rich in 
C20:5 and C22:6 fatty acids. These fatty acids were found 
to be incorporated into the intestinal microsomal lipids. 
The change in lipid content and specific fatty acid type 
resulted in an increased rate of P-450 mediated metabolism 
of benzo[a]pyrene. These two studies indicate that changes 
in microsomal lipid content (68) and lipid type (69) will 
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produce a change (increase) in P-450 activity. It is 
interesting to note that the administration of carbohydrate 
appears to produce the opposite effect on P-450 mediated 
metabolism of drugs, resulting in a decrease of P-450 
activity and a corresponding increase in the duration of 
action of various drugs (35,45,46,47). 
The administration of glucose was shown in these 
studies to have a significant effect on the specific fatty 
acid content within the microsomal membrane as shown in 
Figure 12 and suggest that the hydrophobic environment of 
microsomal P-450 may be altered. The lipid bilayer of the 
microsomal membrane has been shown to influence the confor-
mation of microsomal cytochrome P-450 possibly through the 
iron spin state within the porphoryin ring (22,23,32). The 
binding of substrates to microsomal P-450 produces spectral 
changes which correspond to spin shifts in the iron moiety 
of the cytochrome P-450 enzymes. A shift to a high spin 
1:) 
state is ref erred to as a type 1 spectral shift ( >.. min 420 
nm, >..max 385 nm) and a shift to a low spin state is called 
a type 2 spectral shift ( >.. min 385 nm, >..max 419 nm) (22, 
58,60). The magnitude of spectral change when a substrate 
interacts with P-450 is thus a measure of substrate binding 
(58,60). Since the addition of a substrate to microsomal 
P-450 can shift the spin equilibria of the ferric heme group 
there has been the suggestion that the magnitude of the 
observed binding of a smbstrate may depend on the relative 
----- --- ----------------------~ 
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amounts of P-450 in the high or low spin state before a sub-
strate is added {20,22,23). Thus any perturbation of the 
P-450 spin state equilibria could result in an alteration of 
the binding of a particular substrate. One example of the 
effect of spin equilibria on the binding of a substrate to 
microsomal P-450 is the effect of adrenodoxin on the binding 
of cholesterol to cytochrome P-450. The addition of 
adrenodoxin to a microsomal suspension will shift the spin 
equilibrium of P-450 to the high spin state which results in 
an enhanced binding of cholesterol to P-450 {20). The addi-
tion of pregnenolone to a microsomal suspension will shift 
the spin equilibrium of P-450 to a low spin state which then 
reduces the binding of adrenodoxin (20). 
Gibson et al. (23) have attempted to examine the 
relationship between P-450 spin state equilibria and the 
microsomal lipid. If microsomal P-450 is reconstituted with 
phospholipid and free fatty acids there appears to be a 
shift in the spin equilibrium of P-450 from a low to high 
spin state. The shift in spin state resulted in the 
enhanced binding of type 1 substrates to P-450. Furthermore 
the report showed that the addition of oleic acid would 
shift the spin equilibrium of P-450 to the high spin state 
and that palmitic and stearic acid would shift the equi-
libria to the low spin state (23). These data suggests that 
the fatty acids on the phospholipid play a role in regu-
lating the spin equilibria of P-450 which then affects the 
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binding of particular substrates. The data reported in 
Figure 12 show that specific fatty acid changes (especially 
palmitic and stearic acid) occurred in the microsomal mem-
brane following glucose administration. The changes in 
lipid content and specific fatty acid types (Figures ll,12) 
within the microsomal membrane might be influencing the spin 
state and hence conformational states of membrane bound 
microsomal P-450. If indeed the lipid changes in the mem-
brane are partly responsible for conformational changes in 
microsomal P-450 then it remains possible that conforma-
tional changes in P-450 may be responsible for the observed 
reduction in the binding of hexobarbital and methadone to 
P-450 following glucose administration (Figures 7,8,9,10). 
Whole lipid extracts from the microsomal fraction were 
quantitated following glucose administration. The data 
showed that glucose administration resulted in a significant 
increase in total lipid content (Figure 12) and a signifi-
cant increase in the content of the phospholipids, phospha-
tidylcholine (PC) and phosphatidylethanolamine (PE) as shown 
in Figure 13~. Quantitative changes in these two predominant 
lipids may possibl~ influence the conformational states of 
microsomal P-450 and thus the binding of particular 
substrates to P-450 as shown in Figures 7 and 8. However 
previous studies have shown that while whole lipid is 
important in maintaining the appropriate physical state of 
P-450/it is the fatty acid moiety of the phospholipid that 
.i 
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appears to be the predominant factor in the maintenance of 
P-450 spin state equilibria (23). Thus the alteration of PC 
and PE may not be all that important in the observed binding 
changes observed in these studies (Figures 7,8), but rather 
the quantitative changes in the fatty acid moiety of the 
lipid may be more important in terms of their influence on 
the conformational states of microsomal P-450. 
The second hypothesis for the effect of glucose admin--
istration on the activity of hepatic microsomal P-450 is 
that glucose or some by product of glucose metabolism may 
cause a quantitative change in one or more of the P--450 
enzymes. Although this is a reasonable hypothesis the data 
gathered in our laboratory (Figure 3) and published data 
(46,47) do not suggest that a significant change in the 
amount of P-450 is occurring. No reports have been located 
in the literature of a change in the proportions of the 
multiple forms' of cytochrome P-450 following 48 hr glucose 
administration. If rats are treated for 5 to 7 days with 
fructose or glucose a significant reduction in P-450 content 
can be measured along with a significant reduction in the 
microsomal metabolism of substrates such as ethylmorphine, 
p-Nitroanisole and aniline (44). However 48 hr glucose 
administration will sensitize mice to the effects of pento-
barbital and reduce the metabolic activity of hepatic micro-
somal P-450 as shown here (Figure 1, Table 2) and in other 
studies (45,46,47). Rats are also sensitized to the effects 
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of pentobarbital {Figure 2) by 48 hr glucose administration 
and changes in the binding of hexobarbital and methadone 
(Figures 7,8,9,10) to microsomal P-450 occur after the 
glucose exposure. The changes in microsomal activity in 
mice and the binding changes of drug substrates to rat 
microsomal P-450 observed after glucose administration all 
occur without significant changes in total microsomal P-450 
content. Therefore the data presented here do not support 
the theory that 48 hr glucose administration is altering the 
hepatic microsomal P-450 in a quantitative manner. 
Future studies that may further elucidate the effect of 
glucose administration on the hepatic microsomal·P-450 
system would involve the direct spectral examination of the 
heme spin states of microsomal P-450 in control and glucose 
treated animals. Possible changes in spin states and the 
conformational changes that altered spin equilibria produce 
may provide an explanation for the altered P-450 activity 




The administration of glucose for 48 hrs to mice 
resulted in a shift of the dose response curve for pento-
barbital, an indication that glucose administration signi-
ficantly sensitized the animals to the affects of the drug. 
The administration of glucose also reduced the microsomal 
P-450 catalytic activity as measured by the conversion of 
p-Nitroanisole to p-Nitrophenol. These results were consis-
tent with previously published data and suggest that glucose 
administration may produce its effect on drug duration of 
action through a reduction in the hepatic metabolism of 
various compounds as previously suggested. 
The administration of glucose to rats for 48 hrs also 
resulted in a prolonged effect of pentobarbital induced 
hypnosis. The spectral binding of hexobarbital and metha-
done was found to be significantly reduced following glucose 
administration. The changes in spectral binding were 
observed in the absence of any significant change in the 
microsomal P-450 content. The changes in spectral binding 
of hexobarbital and methadone to P-450 in glucose treated 
animals might suggest that glucose administration may be 
causing a qualitative or a conformational change in hepatic 
microsomal P-450 enzymes. The administration of glucose 
resulted in a significant increase in cytosolic protein 
content which might suggest that glucose is inducing enzymes 
52 
responsible for its metabolism and/or the synthesis of 
lipids from glucose. 
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In an attempt to understand the possible mechanism(s) 
by which glucose exerts its effect on the microsomal P-450 
system, the effects of glucose administration were examined. 
Glucose treatment results in a significant reduction of 
hepatic glycogen content. Glucose treatment did result in 
significant increases in total microsomal lipid, phospho-
lipid, and fatty acid content. Specific microsomal fatty 
acid and phospholipid contents were also measured following 
glucose administration. These results showed there was a 
significant increase in microsomal palmitic, palmitoleic, 
stearic, and oleic acids as well as the phospholipids 
phosphatidylcholine and phosphatidylethanolamine. Changes 
in lipid content and specific fatty acid content have been 
shown to be associated with changes in microsomal P-450 
activity and the binding of various substrates to P-450. 
Changes in fatty acids within the membrane have been 
associated with alterations in the P-450 heme spin states 
which in turn produce qualitative or conformational changes 
in the P-450 enzymes as measured by spectral binding of 
substrates. Conformational changes in P-450 can enhance or 
reduce the binding of various substrates to P-450. Th& data 
reported in these studies suggest that glucose administra-
tion was associated with quantitative changes in specific 
microsomal lipids and that these lipid changes could have 
54 
influenced the activity of microsomal P-450 and the binding 
of drug substrates to P-450. 
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